Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lumicitabine - Alios BioPharma/Janssen

Drug Profile

Lumicitabine - Alios BioPharma/Janssen

Alternative Names: AL 8176; ALS 008176; ALS-8176; JNJ-1575; JNJ-64041575

Latest Information Update: 08 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alios BioPharma
  • Developer Alios BioPharma; Janssen Research & Development
  • Class Antivirals; Esters; Furans; Nucleosides; Pyrimidines
  • Mechanism of Action RNA replicase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections
  • Preclinical Metapneumovirus infections; Parainfluenza virus infections

Most Recent Events

  • 04 Apr 2019 Janssen Research & Development plans a phase IIb trial for Respiratory syncytial virus infections (In children, In infants) in United Kingdom (PO) (EudraCT2016-001641-79 )
  • 15 Nov 2018 Janssen Research & Development terminates a phase II trial in Metapneumovirus infections in USA, Argentina, Australia, Brazil, Bulgaria, France, Italy, Japan, South Korea, Malaysia, Netherlands, Poland, Russia, Spain, Sweden, Taiwan and Ukraine due to corporate decision (NCT03502694)
  • 26 Oct 2018 Janssen terminates the phase II PLUM trial in Respiratory syncytial virus infections (In children, In infants) in USA, Belgium, Ireland, Japan, Portugal, Argentina, Australia, Brazil, Canada, Chile, Colombia, Czechia, Finland, France, Germany, Israel, Italy, South Korea, Malaysia, New Zealand, Panama, Slovakia, Spain, Taiwan, Thailand, Ukraine and United Kingdom (PO) (EudraCT2017-001862-56)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top